Jounce Therapeutics to Present at Upcoming Investor Conferences in September
August 29, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
May 02, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 08, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC trial in the second quarter of 2018 - - Reiterate 2018 strategy to advance clinical and research pipeline to drive...
Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
March 05, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
February 28, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Perry Karsen to Its Board of Directors
January 21, 2016 07:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment,...